NSTGQ vs. SNTI, TVGN, IKT, ONVO, COEP, ALBT, CHRO, GENE, BCDA, and SRNE
Should you be buying NanoString Technologies stock or one of its competitors? The main competitors of NanoString Technologies include Senti Biosciences (SNTI), Tevogen Bio (TVGN), Inhibikase Therapeutics (IKT), Organovo (ONVO), Coeptis Therapeutics (COEP), Avalon GloboCare (ALBT), Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), BioCardia (BCDA), and Sorrento Therapeutics (SRNE). These companies are all part of the "biological products, except diagnostic" industry.
NanoString Technologies (NASDAQ:NSTGQ) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Senti Biosciences received 3 more outperform votes than NanoString Technologies when rated by MarketBeat users.
Senti Biosciences has lower revenue, but higher earnings than NanoString Technologies. Senti Biosciences is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
NanoString Technologies has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500.
76.8% of NanoString Technologies shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of NanoString Technologies shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NanoString Technologies has a net margin of -102.44% compared to Senti Biosciences' net margin of -2,692.82%. NanoString Technologies' return on equity of 0.00% beat Senti Biosciences' return on equity.
Senti Biosciences has a consensus price target of $6.00, suggesting a potential upside of 1,968.97%. Given Senti Biosciences' higher possible upside, analysts plainly believe Senti Biosciences is more favorable than NanoString Technologies.
In the previous week, NanoString Technologies' average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.
Summary
Senti Biosciences beats NanoString Technologies on 9 of the 14 factors compared between the two stocks.
Get NanoString Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSTGQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSTGQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NSTGQ vs. The Competition
NanoString Technologies Competitors List
Related Companies and Tools
